Business Wire

In Competition to Discover Tomorrow’s Proteins, XPRIZE Unveils Semifinalist Teams in XPRIZE Feed the Next Billion

13.7.2021 15:00:00 EEST | Business Wire | Press release

Share

Today, XPRIZE is pleased to announce the 28 semifinalist teams moving forward in XPRIZE Feed the Next Billion. The $15 million competition, launched in December 2020, is aimed at reinventing how humanity will feed future generations by incentivizing the production of structured chicken breast or fish fillet alternatives that replicate or outperform conventional chicken and fish in access, environmental sustainability, animal welfare, nutrition and health, as well as taste and texture.

Selected by the competition’s panel of judges, the 28 semi-finalist teams were chosen based on their technical submissions and represent 14 countries.

Over the next year, semifinalists will work closely with the competition’s ecosystem and sponsors, which include ASPIRE and The Tony Robbins Foundation, as they begin to develop the first iteration of their products. From the Semifinalist teams, up to 10 Finalist teams will be chosen based on the merit of their technical solution prototypes towards the end of 2022 and will split a milestone award of $2.5 million. Finalist teams will enter one last round of solution development before final judging which will award one grand prize team a prize of $7 million, second & third place prizes of $2 and $1 million respectively, and a bonus prize of $2 million. The winning teams will need to create at least twenty-five cuts of structured chicken breast or fish fillet analogs of 115 gram or four ounce that replicate the sensory properties, versatility, and nutritional profile of conventional chicken or fish.

XPRIZE is pleased to share that the following teams have been selected to move forward in the competition:

“Over the past several years, as our global population continues to grow and the demand for meat products increases, it has become clear that our current global food chain cannot keep up,” said Caroline Kolta, XPRIZE Feed the Next Billion Program Lead. “We know we need more nutritious, environmentally-friendly and sustainable alternatives to conventional animal-based products, and that wide scale adoption will require additional innovation continuously being brought to market. I am thrilled about the international cohort of Semifinalists selected to embark on this journey of innovation and exploration to shape a future of food, starting with chicken and fish.”

The XPRIZE Feed the Next Billion judging panel consists of a diverse, international group of tech industry experts working at the highest levels of academia and research. The 8 judges include:

  • Amy C. Rowat, Associate Professor of Integrative Biology and Physiology at the University of California, Los Angeles
  • Brian Jacobson, Assistant Director of Pilot Plant Operations University of Illinois, Integrated Bioprocessing Research Laboratory (IBRL)
  • Dan Blaustein-Rejto, Director of Food & Agriculture at The Breakthrough Institute
  • Kantha Shelke, Ph.D., Founder and Principal at Corvus Blue LLC
  • Dr. Keith Cox, Co-founder and Chief Scientific Officer of Seafood Analytics, Assistant Professor of Marine Fisheries at The University of Alaska Southeast (UAS)
  • Dr. Laura Domigan, Biomaterials Scientist, University of Auckland, New Zealand
  • Dr. Marcos Sanchez-Plata, Associate Professor, Global Food Security - Animal and Food Sciences at Texas Tech University
  • Olivia Ogilvie, Postdoctoral Fellowship in Cellular Agriculture with a Specific Focus on Cultured Meat - The University of Auckland

XPRIZE Feed the Next Billion originated from the Future of Food Impact Roadmap, an in-depth analysis by XPRIZE of global food system challenges, which found alternative proteins at-scale to be a critical impact area requiring significant technological advances, decreased price points, and notable shifts in consumers’ preferences. The competition was then launched with the support of partners including ASPIRE, a part of Abu Dhabi’s Advanced Technology Research Council (ATRC), the technology programme management pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC) which shapes research and development for transformative technology outcomes and defines Abu Dhabi’s R&D strategy, The Tony Robbins Foundation, The Good Food Institute, Foundation for Food and Agriculture, District 3, New Harvest, and Proveg International. Through the development of chicken and fish alternatives, teams competing in the prize will work to ensure that, as the world grows in wealth, the availability of sustainable food can meet the coming demand for food products that allow the next billion to live active and healthy lives.

To learn more about XPRIZE Feed the Next Billion, visit xprize.org/feed.

ABOUT XPRIZE

XPRIZE, a 501(c)(3) nonprofit, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $100 Million XPRIZE Carbon Removal with Elon Musk, $20 Million NRG COSIA Carbon XPRIZE, $15 Million XPRIZE Feed the Next Billion, $10 Million Rainforest XPRIZE, $10 Million ANA Avatar XPRIZE, $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling and $1M Digital Learning Challenge. For more information, visit xprize.org.

About ASPIRE

ASPIRE drives the creation of future transformative technologies as the programme management pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC). ATRC is responsible for defining Abu Dhabi’s research and development strategy, consolidating funds for efficient investment and driving policy and regulation. ASPIRE works in consultation with cross-sector industry stakeholders, universities and research institutes to frame problem statements. It also launches grand challenges and international competitions to solve some of the world’s most pressing issues. ASPIRE brings together exceptional people, ideas, resources and technologies to solve complex challenges. For more information, please visit www.aspireuae.ae.

Connect with us on social media:

LinkedIn

Twitter

Instagram

ABOUT THE TONY ROBBINS FOUNDATION

Founded in 1991, The Tony Robbins Foundation is a nonprofit organization created to empower individuals and organizations to make a significant difference in the quality of life of people often forgotten. Through global programs and initiatives, The Tony Robbins Foundation is dedicated to creating positive changes in the lives of youth, seniors, the hungry, homeless and the imprisoned population. The Foundation helps provide millions of meals globally each year, has awarded over 2,000 grants and other resources to health and human services organizations, implemented curriculum in 1,700 plus correctional facilities and gathered thousands of young leaders from around the world with its teen programs. For more information, visit www.thetonyrobbinsfoundation.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Caden Kinard, 949-280-0182
caden.kinard@xprize.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 16:00:00 EEST | Press release

Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is strengthening its position through the acquisition of a VCSEL company for short-range communications five years ago and the completion of 100G (25G×4) class technology. Furthermore, Seoul Viosys is ex

vVARDIS Announces Investment from Apollo —Achieves Unicorn Status27.4.2026 15:51:00 EEST | Press release

vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulations clinically proven to treat tooth decay. Curodont™ supports enamel repair by facilitating the formation of crystalline mineral structure throughout the affected area, giving dental professionals an easy-to-use, restorative opti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye